News
Astrazeneca: Results from the Phase III clinical trial indicate that the blockbuster immunotherapy drug Imfinzi (durvalumab) showed improvement in the primary endpoint
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments